Basiliximab, previously known as CHI 621 and possessing the chemical identifier 179045-86-4, represents a antibody agent utilized primarily in suppressing acute repudiation following organ grafting . This engineered immunoglobulin specifically targets the interleukin-2 (IL-2) receptor , effectively hindering IL-2 communication and subsequently less